RSS-Feed abonnieren
DOI: 10.1055/s-2001-14096
© Georg Thieme Verlag Stuttgart · New York
Prädiktion und Prävention des Typ-1-Diabetes
Prediction and prevention of type 1 diabetesPublikationsverlauf
Publikationsdatum:
31. Dezember 2001 (online)
![](https://www.thieme-connect.de/media/dmw/200120/lookinside/thumbnails/10.1055-s-2001-14096-1.jpg)
Die klinische Manifestation des Typ-1-Diabetes mellitus ist der Endpunkt einer Entzündung und autoimmunen Zerstörung der insulinproduzierenden Betazellen des Pankreas. Bereits viele Jahre vor Ausbruch der Erkrankung treten bei Betroffenen Insel-Autoantikörper auf, die in Venen- oder Kapillarblut detektierbar sind. Dies ermöglicht eine frühzeitige Diagnose der Autoimmunerkrankung noch vor dem Auftreten von klinischen Symptomen der Hyperglykämie.
In der vorliegenden Übersicht werden Strategien der Früherkennung diskutiert und Empfehlungen zum Einsatz von immunologischen, genetischen bzw. metabolischen Markern zur Risikoabschätzung des Typ-1-Diabetes gegeben. Des weiteren werden laufende Studien zur Prävention des Typ-1-Diabetes vorgestellt.
Literatur
- 1 Akerblom H J, Virtanen S M, Hämäläinen. et al .Modulation of the appearance of diabetes associated autoantibodies in the nutritional prevention of type 1 diabetes (TRIGR) project. Abstract book 4th immunology of Diabetes Society Congress 1999: 123
- 2 Atkinson M A, MacLaren N K. The pathogenisis of insulin-dependent diabetes mellitus. New England Journal of Medicine. 1994; 331 1428-1436
- 3 Bingley P J, Bonifacio E, Williams A J, Genovese S, Bottazzo G F, Gale E A. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes. 1997; 46 1701-1710
- 4 Bingley P J, Bonifacio E, Ziegler A G, Schatz D A, Atkinson M A, Eisenbarth G S. on behalf of the Immunology of Diabetes Society . Proposed Guidelines on Screening for Risk of Type 1 Diabetes. Diabetes Care. 2001; 24 398
- 5 Christie M R, Roll U, Payton M A, Hatfield E C, Ziegler A G. Validity of screening for individuals at risk for type I diabetes by combined analysis of antibodies to recombinant proteins. Diabetes Care. 1997; 20 965-970
- 6 Dittler J, Seidel D, Schenker M, Ziegler A G. GADIA2-combi determination as first-line screening for improved prediction of type 1 diabetes in relatives. Diabetes. 1998; 47 592-597
- 7 Feeney S J, Myers M A, Mackay I R, Zimmet P Z, Howard N, Verge C F, Rowley M J. Evaluation of ICA512As in combination with other islet cell autoantibodies at the onset of IDDM. Diabetes Care. 1997; 20 1403-7
- 8 Füchtenbusch M, Ferber K, Standl E, Ziegler A G. Prediction of type 1 diabetes postpartum in patients with gestational diabetes mellitus by combined islet cell autoantibody screening: a prospective multicenter study. Diabetes. 1997; 46 1459-1467
- 9 Füchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler A G. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: The Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia. 1998; 41 536-541
- 10 Ido Y, Vindigni A, Chang K. et al . Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science. 1997; 277 563-566
- 11 Lohmann T, Seissler J, Verlohren H J, Schroder S, Rotger J, Dahn K, Morgenthaler N, Scherbaum W A. Distinct genetic and immunological features in patients with onset of IDDM before and after age 40. Diabetes Care. 1997; 20 524-529
- 12 Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia. 1994; 37 552-558
- 13 Rewers M, Bugawan T L, Norris J M, Blair A, Beaty B, Hoffman M, McDuffie R S Jr, Hamman R F, Klingensmith G, Eisenbarth G S, Erlich H A. Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY). Diabetologia. 1996; 39 807-812
- 14 Roll U, Ziegler A G. Combined antibody screening for improved prediction of IDDM - Modern strategies. Exp Clin Endocrinol Diabetes. 1997; 105 1-14
- 15 Schatz D, Krischer J, Horne G, Riley W, Spillar R, Silverstein J, Winter W, Muir A, Drovanesian D, Shah S, Malone J, MacLaren N. Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as in unaffected relatives. J Clin Invest. 1994; 93 2403-2407
- 16 Schenker M, Hummel M, Ferber K, Walter M, Keller E, Albert E D, Janka H U, Kastendiek C, Sorger M, Louwen F, Ziegler A G. Early expression and high prevalence of islet autoantibodies for DR3/4 heterozygous and DR4/4 homozygous offspring of parents with Type I diabetes: The German BABYDIAB study. Diabetologia. 1999; 42 671-677
- 17 Schloot N C, Pozzilli P, Mandrup-Poulsen T. Immune markers for monitoring the progression of autoimmune disease. Diabetes Metab Res Rev. 1999; 15 141-145
- 18 Seissler J, Hering B, Richter W, Gluck M, Yassin N, Bretzel R G, Boehm B O, Federlin K, Scherbaum W A. Antibodies to the M(r) 64,000 (64K) protein in islet cell antibody positive non-diabetic individuals indicate high risk for impaired beta-cell function. Diabetologia. 1992; 35 550-554
- 19 Strebelow M, Schlosser M, Ziegler B, Rjasanowski I, Ziegler M. Karlsburg Type I diabetes risk study of a general population: frequencies and interactions of the four major Type I diabetes-associated autoantibodies studied in 9419 schoolchildren. Diabetologia. 1999; 42 661-670
- 20 The Eurodiab Substudy 2 Study Group . Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus. Diabetologia. 1999; 42 51-54
- 21 Verge C F, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Chase H P, Eisenbarth G S. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun. 1996; 9 379-383
- 22 Verge C F, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson R A, Chase H P, Eisenbarth G S. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes. 1996; 45 926-933
- 23 Wahren J, Johansson B L. Ernst-Friedrich-Pfeiffer Memorial Lecture. New aspects of C-peptide physiology. Horm Metab Res. 1998; 30 A2-5
- 24 Ziegler A G, Hummel M, Schenker M, Bonifacio E. Autoantibody Appearance and Risk for the Development of Childhood Diabetes in Offspring of Parents with Type 1 Diabetes: The German BABY-DIAB Study. Diabetes. 1999; 48 460-468
Korrespondenz
Prof. Dr. med. Anette-G. Ziegler
Institut für Diabetesforschung und 3.
Med. Abteilung, Krankenhaus München-Schwabing
Kölner Platz 1
80804 München
Telefon: 089/30793114
Fax: 089/3081733
eMail: prevent.diabetes@lrz.uni-muenchen.de